Ascendant Diagnostics | Tear-Based Breast Cancer Diagnosis
Ascendant Dx is an early stage biotechnology company that was formed in September of 2010 with a focus on developing innovative new approaches to improve the diagnosis of serious disease and conditions.
Ascendant’s first product in development is an in vitro diagnostic assay to detect early stage breast cancer utilizing the proteomic profile present in tears. Implementation of our test in the market place will lead to greater rates of survivability by increasing early detection of breast cancer.
We believe our simple, non-invasive tear-based collection method will rapidly lead to increased participation by individuals who choose not to utilize currently available yearly screening methods.
- Life Sciences
- 535 W. Research Center Blvd.
- Fayetteville, AR 72701
- Omid Moghadam,
- Chief Executive Officer
- Anna Daily, PhD
- Senior Scientist
- Kimberley Fuller,
- Director of Market Research
- and Business Development
The 2016 Youth Entrepreur Showcase brought together the top 25 student teams, representing students in grades 5-8, for the competition's Expo Day. More than 200 teams submitted business plans for the competition and the top 25 were brought to Little Rock.
LineGuard Med, the medical device startup from Little Rock entrepreneur Spencer Jones, has added Vance Clement of Fayetteville's BlueInGreen as its chief operating officer, the company announced.
The Arkansas Research Alliance has named Sonja Hubbard, president and CEO of Texarkana's E-Z Mart Stores Inc., chairman of its board of directors and added four new board members.
A recent item in the Washington Post about driver retention in the trucking industry mentioned several Arkansas sources.